|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Transplantation in autoimmune liver diseases显示文摘Liver transplantation remains an effective treatment for those with end-stage disease and with intractable liver-related symptoms.The shortage of organs for transplantation has resulted in the need for rationing.A variety of approaches to selection and allocation have been developed and vary from country to country.The shortage of donors has meant that new approaches have to be adopted to make maximal use of the available organs;these include splitting grafts,use of extended criteria livers,livers from non-heart-beating donors and from living donors.Post transplantation,most patients will need life-long immunosuppression,although a small proportion can have immunosuppression successfully withdrawn.Newer immunosuppressive drugs and different strategies may allow a more targeted approach with a reduction in side-effects and so improve the patient and graft survival.For autoimmune diseases,transplantation is associated with significant improvement in the quality and length of life.Disease may recur after transplantation and may affect patient and graft survival. | Marcus Mottershead James Neuberger | 2008 | World Journal of Gastroenterology2008，14，21： | 4 |
| 2 | Donor transmitted and de novo cancer after liver transplantation显示文摘Cancers in solid organ recipients may be classified as donor transmitted,donor derived,de novo or recurrent.The risk of donor-transmitted cancer is very low and can be reduced by careful screening of the donor but cannot be abolished and,in the United Kingdom series is less than 0.03%.For donors with a known history of cancer,the risks will depend on the nature of the cancer,the interventions given and the interval between diagnosis and organ donation.The risks of cancer transmission must be balanced against the risks of death awaiting a new graft and strict adherence to current guidelines may result increased patient death.Organs from selected patients,even with high-grade central nervous system(CNS)malignancy and after a shunt,can,in some circumstances,be considered.Of potential donors with non-CNS cancers,whether organs may be safely used again depends on the nature of the cancer,the treatment and interval.Data are scarce about the most appropriate treatment when donor transmitted cancer is diagnosed:sometimes substitution of agents and reduction of the immunosuppressive load may be adequate and the impact of graft removal should be considered but not always indicated.Liver al-lograft recipients are at increased risk of some de novo cancers,especially those grafted for alcohol-related liver disease and hepatitis C virus infection.The risk of lymphoproliferative disease and cancers of the skin,upper airway and bowel are increased but not breast.Recipients should be advised to avoid risk behavior and monitored appropriately. | Rajeev Desai James Neuberger | 2014 | World Journal of Gastroenterology2014，20，20： | 3 |
| 3 | Cardiovascular morbidity and mortality after orthotopic liver transplantation显示文摘 | Simon D. Johnston Joan K. Morris Rob Cramb Bridget K. Gunson James Neuberger | 2002 | Transplantation2002，，6： | 2 |
| 4 | Autoimmune liver disease, autoimmunity and liver transplantation显示文摘 | Marco Carbone James M. Neuberger | 2014 | Journal of Hepatology2014，，： | 2 |
| 5 | Cancer Transmission From Organ Donors—Unavoidable But Low Risk显示文摘 | Rajeev Desai Dave Collett Christopher J. Watson Philip Johnson Tim Evans James Neuberger | 2012 | Transplantation Journal2012，，12： | 2 |
| 6 | How regenerative medicine and tissue engineering may complement the available armamentarium in gastroenterology?显示文摘The increasing shortage of donors and the adverse effects of immunosuppression have restricted the impact of solid organ transplantation.Despite the initial promising developments in xenotransplantation,roadblocks still need to be overcome and this form of organ support remains a long way from clinical practice.While hepatocyte transplantation may be effectively correct metabolic defects,it is far less effective in restoring liver function than liver transplantation.Tissue engineering,using extracellular matrix scaffolds with an intact but decellularized vascular network that is repopulated with autologous or allogeneic stem cells and/or adult cells,holds great promise for the treatment of failure of organs within gastrointestinal tract,such as endstage liver disease,pancreatic insufficiency,bowel failure and type 1 diabetes.Particularly in the liver field,where there is a significant mortality of patients awaiting transplant,human bioengineering may offer a source of readily available organs for transplantation.The use of autologous cells will mitigate the need for long term immunosuppression thus removing a major hurdle in transplantation. | Marco Carbone Jan Lerut James Neuberger | 2012 | World Journal of Gastroenterology2012，18，47： | 2 |
| 7 | Reducing the Risks of Cardiovascular Disease in Liver Allograft Recipients显示文摘 | George Mells James Neuberger | 2007 | Transplantation2007，，9： | 2 |
| 8 | Phase Ⅲ trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial(E1193) 显示文摘 | Sledge GW Neuberg D Bernardo P | 2003 | J Clin Oncol2003，21，4： | 1 |
| 9 | Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma显示文摘 | Gribben JG Freedman AS Neuberg D | 1991 | N Engl Med1991，325，： | 1 |
| 10 | Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90-12 ) : phase Ⅱ trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus显示文摘 | Minsky BD Neuberg D Kelsen DP | 1999 | Int J Radiat Oncol Biol Phys1999，43，3： | 1 |
| 11 | Management of atrial fibrillation in patients with heart failure显示文摘 | Neuberger HR Mewis C Veldhuisen DJ | 2007 | Eur Heart J2007，28，： | 1 |
| 12 | Acute respiratory symptoms in workers exposed to vanadium -- rich fuel-- oil ash 显示文摘 | Woodin MA Liu Y Neuberg D | 2000 | Am J Ind Med2000，37，4： | 1 |
| 13 | Hedging long run term exposures with multiple short term futures contracts 显示文摘 | Neuberger A | 1999 | Review of Financial Studies1999，12，3： | 1 |
| 14 | Phase II trial of doeetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxie chemotherapy: The Eastern Cooperative Oncology Group (ECOG) results of protocol E1293 显示文摘 | Einzig AI Neuberg D Remick SC | 1996 | Med Oncol1996，13，： | 1 |
| 15 | Serum hyaluronic acid following liver transplantation : evidence of hepatic endothelial damage 显示文摘 | Adams DH Wang L Neuberger JM | 1989 | Transplant Proceedings1989，21，1： | 1 |
| 16 | Manage- ment of atrial fibrillation in patients with heart failure 显示文摘 | Neuberger HR Mewis C van Veldhuisen DJ | 2007 | Eur Heart J2007，28，21： | 1 |
| 17 | Chronic atrial dilation,electrical remodeling,and atrial fibrillation in the goat 显示文摘 | Neuberger HR Schotten U Blaauw Y | 2006 | J Am Coll Cardiol2006，47，3： | 1 |
| 18 | Phase Ⅲ trial of doxorubicin vs paclitaxel vs doxorubicin + paclitaxel as first- line therapy for metastatic cancer: an intergroup trial显示文摘 | Sledge G N Neuberg D Ingle S | 1997 | J Clin Oncol1997，16，： | 1 |
| 19 | 显示文摘 | Guinan EC Boussiotis VA Neuberg D | 1999 | N Engl J Med1999，340，22： | 1 |
| 20 | Codon bias targets mutation显示文摘 | Wagner SD Milstein C Neuberger MS | 1995 | Naturs1995，376，6543： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员